Prediction of P-tau/Aβ42 in the cerebrospinal fluid with blood microRNAs in Alzheimer’s disease
Authors:
Open Access
- 15 November 2021
- journal article
- research article
- Published by Springer Nature in BMC Medicine
- Vol. 19 (1) , 1-15
Abstract
Background: The most common biomarkers of Alzheimer’s disease (AD) are amyloid β (Aβ) and tau, detected in cerebrospinal fluid (CSF) or with positron emission tomography imaging. However, these procedures are invasive and expensive, which hamper their availability to the general population. Here, we report a panel of microRNAs (miRNAs) in serum that can predict P-tau/Aβ42 in CSF and readily differentiate AD from other dementias, including vascular dementia (VaD), Parkinson disease dementia (PDD), behavioral variant frontotemporal dementia (bvFTD), and dementia with Lewy body (DLB). Methods: RNA samples were extracted from the participant’s blood. P-tau/Aβ42 of CSF was examined for diagnostic purposes. A pilot study (controls, 21; AD, 23), followed by second (controls, 216; AD, 190) and third groups (controls, 153; AD, 151), is used to establish and verify a predictive model of P-tau/Aβ42 in CSF. The test is then applied to a fourth group of patients with different dementias (controls, 139; AD,155; amnestic mild cognitive impairment [aMCI], 55; VaD, 51; PDD, 53; bvFTD, 53; DLB, 52) to assess its diagnostic capacity. Results: In the pilot study, 29 upregulated and 31 downregulated miRNAs in the AD group were found. In Dataset 2, these miRNAs were then included as independent variables in the linear regression model. A seven-microRNA panel (miR-139-3p, miR-143-3p, miR-146a-5p, miR-485-5p, miR-10a-5P, miR-26b-5p, and miR-451a-5p) accurately predicted values of P-tau/Aβ42 of CSF. In Datasets 3 and 4, by applying the predicted P-tau/Aβ42, the predictive model successfully differentiates AD from controls and VaD, PDD, bvFTD, and DLB. Conclusions: This study suggests that the panel of microRNAs is a promising substitute for traditional measurement of P-tau/Aβ42 in CSF as an effective biomarker of AD.Keywords
Funding Information
- National Natural Science Foundation of China (81870825, 82071194)
- Beijing Brain Initiative from Beijing Municipal Science & Technology Commission (Z201100005520016)
- Natural Science Foundation of Beijing Municipality (7202061)
This publication has 75 references indexed in Scilit:
- Alteration of the microRNA network during the progression of Alzheimer's diseaseEMBO Molecular Medicine, 2013
- Infernal 1.1: 100-fold faster RNA homology searchesBioinformatics, 2013
- Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementiaBrain, 2011
- Identifying and validating biomarkers for Alzheimer's diseaseTrends in Biotechnology, 2011
- MicroRNA-101 Regulates Amyloid Precursor Protein Expression in Hippocampal NeuronsJournal of Biological Chemistry, 2010
- MicroRNA control of signal transductionNature Reviews Molecular Cell Biology, 2010
- Ultrafast and memory-efficient alignment of short DNA sequences to the human genomeGenome Biology, 2009
- c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolismNature, 2009
- Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/β-secretase expressionProceedings of the National Academy of Sciences, 2008
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001